\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesThe call for proposals for the new Knowledge & Innovation Community (KIC): EIT Culture & Creativity has been officially launched. This call invites consortia of organisations and CCSI industry and sectoral leaders to put forward their vision and strategy for the new EIT Culture & Creativity by bringing education, research and business together.
The deadline for submitting applications for the call for proposals for EIT Culture & Creativity is Thursday 24 March 2022, 17:00 CET.
More information on the launch of this call can be found here.
In the context of the opening of this call, EIT will organize a series of webinars that will help you shape your proposals for EIT Culture & Creativity. The four webinars will cover all aspects from the EIT Community: from the key activities to the EIT Funding Model.
More information on these webinars can be found on the EIT's webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
